Alimera Sciences Profit Margin 2009-2021 | ALIM
Current and historical gross margin, operating margin and net profit margin for Alimera Sciences (ALIM) over the last 10 years. Profit margin can be defined as the percentage of revenue that a company retains as income after the deduction of expenses. Alimera Sciences net profit margin as of June 30, 2021 is 3.92%.
|Alimera Sciences Annual Profit Margins
|Alimera Sciences Quarterly Profit Margins
||Medical - Biomedical and Genetics
Alimera Sciences, Inc., based in Alpharetta, Georgia, is a biopharmaceutical company that specializes in the research, development and commercialization of prescription ophthalmic pharmaceuticals. The Company is presently focused on diseases affecting the back of the eye, or retina because it believes these diseases are not well treated with current therapies and represent a significant market opportunity. Its product candidate Iluvien(R) is an intravitreal insert containing fluocinolone acetonide, a non-proprietary corticosteroid with demonstrated efficacy in the treatment of ocular disease. Iluvien is in development for the treatment of diabetic macular edema (DME). DME is a disease of the retina that affects individuals with diabetes and can lead to severe vision loss and blindness.